
Oncology NEWS International
- Oncology NEWS International Vol 7 No 7
- Volume 7
- Issue 7
Avon’s Pink Ribbon Cosmetics Case Carries Make-up And a Message
NEW YORK--Avon’s Breast Cancer Awareness Crusade is combining health and beauty with the introduction of its newest fundraising product, the Avon Pink Ribbon Cosmetics Case.
NEW YORK--Avons Breast Cancer Awareness Crusade is combining health and beauty with the introduction of its newest fundraising product, the Avon Pink Ribbon Cosmetics Case.
The cosmetics case joins Avons other pink ribbon products, including a pin and coffee mug, proceeds of which have helped Avons Crusade raise more than $25 million for US nonprofit breast health programs nationwide and contributed to the Avon Worldwide Fund for Womens Health, a global initiative that is expected to reach the $50 million fundraising mark in 1998.
"The message we are bringing to women this year is: Claim Your Health, Claim Your Beauty," said Joanne Mazurki, director of Avons Crusade. "We are reminding women that along with their daily beauty routines, they should be equally diligent about practicing good breast health."
The Cosmetics Case will be available in October at a price of $3.00. To order, contact the nearest Avon Sales Representative or call 1-800-FOR-AVON.
Articles in this issue
almost 28 years ago
Calling the National Cancer Institutealmost 28 years ago
Six Cycles of AT Found Safe in Advanced Breast Canceralmost 28 years ago
New Drug Promising in Advanced Pancreatic Canceralmost 28 years ago
Herceptin/Chemo Effective in Metastatic Breast Canceralmost 28 years ago
Virtual Reality Exhibit Simulates Cancer Fatiguealmost 28 years ago
New Director of AIDS Researchalmost 28 years ago
Exhibit Explores Healing Power of Creating Artworkalmost 28 years ago
Update on Trials of Thrombopoietin for Platelet Recoveryalmost 28 years ago
Amifostine Reduces Xerostomia After RT for Head and Neck Canceralmost 28 years ago
National Survey Documents Gap in Quality of HIV/AIDS CareRelated Content


98 A Phase 1/2 Trial of LY4064809, A Pan-Mutant-Selective PI3Kα Inhibitor in HR+/HER2− Advanced Breast Cancer, Updated Results From PIKALO-1





















































